Comparative in vitro activities of ciprofloxacin, clinafloxacin, gatifloxacin, levofloxacin, moxifloxacin, and trovafloxacin against Klebsiella pneumoniae, Klebsiella oxytoca, Enterobacter cloacae, and Enterobacter aerogenes clinical isolates with alterations in GyrA and ParC proteins

Antimicrobial Agents and Chemotherapy

Volumn 43, Issue 8, 1999, Pages 2051-2055

  Brisse, Sylvain ^a   Milatovic, Dana ^a   Fluit, Ad C ^a   Verhoef, Jan ^a   Martin, Nele ^b   Scheuring, Sybille ^b   Köhrer, Karl ^b   Schmitz, Franz Josef ^a,b  

^a UTRECHT UNIVERSITY   (Netherlands)

^b UNIVERSITY HOSPITAL DÜSSELDORF   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL PROTEIN; CIPROFLOXACIN; CLINAFLOXACIN; DNA TOPOISOMERASE (ATP HYDROLYSING); GATIFLOXACIN; LEVOFLOXACIN; MOXIFLOXACIN; TROVAFLOXACIN;

AMINO ACID SUBSTITUTION; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL GENE; BACTERIUM ISOLATE; ENTEROBACTER AEROGENES; ENTEROBACTER CLOACAE; KLEBSIELLA OXYTOCA; KLEBSIELLA PNEUMONIAE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL;

EID: 0032840209     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.43.8.2051     Document Type: Article

References (21)

1. Alarcon, T., J. Pita, M. Lopez-Brea, and L. J. Piddock. 1993. High-level quinolone resistance amongst clinical isolates of Escherichia coli and Klebsiella pneumoniae from Spain. J. Antimicrob. Chemother. 32:605-609.
2. Bauernfeind, A. 1997. Comparison of the antibacterial activities of the quinolones Bay 12-8039, gatifloxacin (AM 1155), trovafloxacin, clinafloxacin, levofloxacin and ciprofloxacin. J. Antimicrob. Chemother. 40:639-651.
3. Bauernfeind, A., M. Abele-Horn, P. Emmerling, and R. Jungwirth. 1994. Multiclonal emergence of ciprofloxacin-resistant clinical isolates of Escherichia coli and Klebsiella pneumoniae. J. Antimicrob. Chemother. 34:1074-1076.
4. Belland, R. J., S. G. Morrison, C. Ison, and W. M. Huang. 1994. Neisseria gonorrhoeae acquires mutations in analogous regions of gyrA and parC in fluoroquinolone-resistant isolates. Mol. Microbiol. 14:371-380.
5. Deguchi, T., M. Yasuda, M. Asano, K. Tada, H. Iwata, H. Komeda, T. Ezaki, I. Saito, and Y. Kawada. 1995. DNA gyrase mutations in quinolone-resistant clinical isolates of Neisseria gonorrhoeae. Antimicrob. Agents Chemother. 39:561-563.
6. Deguchi, T., M. Yasuda, M. Nakano, S. Ozeki, T. Ezaki, I. Saito, and Y. Kawada. 1996. Quinolone-resistant Neisseria gonorrhoeae: correlation of alterations in the GyrA subunit of DNA gyrase and the ParC subunit of topoisomerase IV with antimicrobial susceptibility profiles. Antimicrob. Agents Chemother. 40:1020-1023.
7. Deguchi, T., A. Fukuoka, M. Yasuda, M. Nakano, S. Ozeki, E. Kanematsu, Y. Nishino, S. Ishihara, Y. Ban, and Y. Kawada. 1997. Alterations in the GyrA subunit of DNA gyrase and the ParC subunit of topoisomerase IV in quinolone-resistant clinical isolates of Klebsiella pneumoniae. Antimicrob. Agents Chemother. 41:699-701.
8. Deguchi, T., M. Yasuda, M. Nakano, S. Ozeki, E. Kanematsu, Y. Nishino, S. Ishihara, and Y. Kawada. 1997. Detection of mutations in the gyrA and parC genes in quinolone-resistant clinical isolates of Enterobacter cloacae. J. Antimicrob. Chemother. 40:543-549.
9. Dimri, G. P., and H. K. Das. 1990. Cloning and sequence analysis of gyrA gene of Klebsiella pneumoniae. Nucleic Acid Res. 18:151-156.
10. Gootz, T. D., and K. E. Brighty. 1998. Chemistry and mechanism of action of the quinolone antibacterials, p. 29-80. In V. T. Andriole (ed.), The quinolones. Academic Press, San Diego, Calif.
11. Heisig, P., H. Schedletzky, and H. Falkenstein-Paul. 1993. Mutations in the gyrA gene of a highly fluoroquinolone-resistant clinical isolate of Escherichia coli. Antimicrob. Agents Chemother. 37:696-701.
12. Hooper, D. C. 1995. Bacterial resistance to fluoroquinolones: mechanisms and patterns. Adv. Exp. Med. Biol. 390:49-57.
13. Jones, R. N., E. N. Kehrberg, M. E. Erwin, S. C. Anderson, and the Fluoroquinolone Resistance Surveillance Group. 1994. Prevalence of important pathogens and antimicrobial activity of parenteral drugs at numerous medical centers in the United States. Diagn. Microbiol. Infect. Dis. 19:203-215.
14. Kato, J., Y. Nishimura, R. Imamura, H. Niki, S. Hiraga, and H. Suzuki. 1990. New topoisomerase essential for chromosome segregation in E. coli. Cell 63:393-404.
15. Khodursky, A. B., E. L. Zechiedrich, and N. R. Cozzarelli. 1995. Topoisomerase IV is a target of quinolones in Escherichia coli. Proc. Natl. Acad. Sci. USA 92:11801-11805.
16. Kumagai, Y., J. I. Kato, K. Hoshino, T. Akasaka, K. Sato, and H. Ikeda. 1996. Quinolone-resistant mutants of Escherichia coli DNA topoisomerase IV parC gene. Antimicrob. Agents Chemother. 40:710-714.
17. National Committee for Clinical Laboratory Standards. 1997. Methods for dilution antimicrobial tests for bacteria that grow aerobically. Approved standard M7-A4. National Committee for Clinical Laboratory Standards, Wayne, Pa.
18. Schmitz, F. J., M. E. Jones, B. Hofmann, B. Hansen, S. Scheuring, M. Luckefahr, A. Fluit, J. Verhoef, U. Hadding, H. P. Heinz, and K. Kohrer. 1998. Characterization of grlA, grlB, gyrA, and gyrB mutations in 116 unrelated isolates of Staphylococcus aureus and effects of mutations on ciprofloxacin MIC. Antimicrob. Agents Chemother. 42:1249-1252.
19. Schmitz, F. J., E. Lindenlauf, B. Hofmann, A. C. Fluit, J. Verhoef, H. P. Heinz, and M. E. Jones. 1998. The prevalence of low- and high-level mupirocin resistance in staphylococci from 19 European hospitals. J. Antimicrob. Chemother. 42:489-495.
20. Weigel, L. M., C. D. Steward, and F. C. Tenover. 1998. gyrA mutations associated with fluoroquinolone resistance in eight species of Enterobacteriaceae. Antimicrob. Agents Chemother. 42:2661-2667.
21. Yoshida, H., M. Bogaki, M. Nakamura, and S. Nakamura. 1990. Quinolone resistance-determining region in the DNA gyrase gyrA gene of Escherichia coli. Antimicrob. Agents Chemother. 34:1271-1272.